![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Billin Andrew N
Publisher: Informa Healthcare
ISSN: 1354-3784
Source: Expert Opinion on Investigational Drugs, Vol.17, Iss.10, 2008-10, pp. : 1465-1471
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk
Current Pharmaceutical Design, Vol. 23, Iss. 6, 2017-03 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Liraglutide looking good in type 2 diabetes
Inpharma, Vol. 1, Iss. 1459, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
PPAR- agonists: therapeutic role in diabetes, inflammation and cancer
Trends in Pharmacological Sciences, Vol. 21, Iss. 12, 2000-12 ,pp. :